ABSTRACT

Market access is the fourth hurdle in the drug development process and the primary driver for global income of any new drug. Without a strategy in place for pricing, showing value for effectiveness and an understanding of the target purchasers’ needs, the drug will fail to reach its intended market value. Introduction to Market Access for Pharmaceuticals is based on an accredited course in this area, taken from the European Market Access University Diploma (EMAUD), and is affiliated with Aix Marseille University.

Key Features:

  • The first guide to market access for pharmaceuticals based on tested teaching materials
  • Addresses both pharmaceutical and vaccine products
  • Includes case studies and scenarios
  • Covers market access consdierations for Western Europe, the USA, Japan and China
  • Explains the impact the changing healthcare market will have on your product
  • chapter 1|4 pages

    Health as a Good

    chapter 2|8 pages

    Decision-Making in Public Health

    chapter 3|14 pages

    Definitions and Concepts

    chapter 4|10 pages

    HTA Decision Analysis Framework

    chapter 5|10 pages

    Early HTA Advice

    chapter 6|24 pages

    Overview of Market Access Agreements

    chapter 7|8 pages

    External Reference Pricing

    chapter 8|12 pages

    Gap between Payers and Regulators

    chapter 9|6 pages

    Early Access Programs

    chapter 10|10 pages

    Market Access of Orphan Drugs

    chapter 12|6 pages

    France

    chapter 13|4 pages

    Germany

    chapter 14|4 pages

    Italy

    chapter 15|4 pages

    Spain

    chapter 16|6 pages

    Sweden

    chapter 17|6 pages

    United Kingdom

    chapter 18|6 pages

    Belgium

    chapter 19|6 pages

    The United States

    chapter 20|4 pages

    Japan

    chapter 21|4 pages

    China